中國抗體(03681.HK)與D2M訂立創新型靶點藥合作協議
中國抗體-B(03681.HK)公布,與D2M訂立有關創新型藥物靶點識別的合作協議,公司有權根據優先靶點選擇機制對公司從D2M靶點識別工作的原始結果中選擇的合格藥物靶點進行後續研究、發展及商業化;D2M須為公司物色創新型藥物靶點,以評估有關發現的科學及商業價值初步為期三年。同時,公司將以500萬美元購買D2M 2,778萬股優先股,持股38.17%。
D2M是一家專門開發基因驅動靶點識別平台,以及就治療或預防人類疾病針對該等靶點發現、發展及商業化療法及治療的公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.